David Escors
Overview
Explore the profile of David Escors including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
3388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez C, Chocarro L, Echaide M, Ausin K, Escors D, Kochan G
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125578
CX3CL1 is one of the 50 up-to-date identified and characterized chemokines. While other chemokines are produced as small, secreted proteins, CX3CL1 (fractalkine) is synthetized as a transmembrane protein which also...
2.
Chocarro L, Blanco E, Fernandez-Rubio L, Garnica M, Zuazo M, Garcia M, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1791-1816.
PMID: 39030301
Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state...
3.
Blanco E, Escors D, Kochan G
Methods Cell Biol
. 2024 Mar;
184:85-96.
PMID: 38555160
Myeloid-derived suppressor cells (MDSCs) are major promoters of progression and metastasis in cancer. MDSCs inhibit the anti-tumor immune response through multiple mechanisms. The main MDSC functions in cancer are related...
4.
Blanco E, Silva-Pilipich N, Bocanegra A, Chocarro L, Procopio A, Ausin K, et al.
Br J Cancer
. 2024 Jan;
130(5):869-879.
PMID: 38195888
Background: Previous studies have shown that functional systemic immunity is required for the efficacy of PD-1/PD-L1 blockade immunotherapies in cancer. Hence, systemic reprogramming of immunosuppressive dysfunctional myeloid cells could overcome...
5.
Arrazubi V, Goni S, Gonzalez-Borja I, Hernandez-Garcia I, Arasanz H, Perez-Sanz J, et al.
Head Neck
. 2023 Oct;
45(12):3075-3085.
PMID: 37792371
Background: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. Methods: This was a prospective observational study including 25 patients...
6.
Redondo-Munoz M, Rodriguez-Baena F, Aldaz P, Caballe-Mestres A, Moncho-Amor V, Otaegi-Ugartemendia M, et al.
Nat Metab
. 2023 Aug;
5(9):1544-1562.
PMID: 37563469
Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF inhibitor (BRAFi) treatment contributes to...
7.
Arasanz H, Chocarro L, Fernandez-Rubio L, Blanco E, Bocanegra A, Echaide M, et al.
Int J Mol Sci
. 2023 Jun;
24(12).
PMID: 37373003
Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development...
8.
Bocanegra A, Fernandez-Hinojal G, Ajona D, Blanco E, Zuazo M, Garnica M, et al.
EMBO Rep
. 2023 Jun;
24(8):e55884.
PMID: 37366231
Recent studies highlight the importance of baseline functional immunity for immune checkpoint blockade therapies. High-dimensional systemic immune profiling is performed in a cohort of non-small-cell lung cancer patients undergoing PD-L1/PD-1...
9.
Echaide M, Chocarro de Erauso L, Bocanegra A, Blanco E, Kochan G, Escors D
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36983017
The application of BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection has constituted a determinant resource to control the COVID-19 pandemic. Since the beginning of 2021, millions of doses have been...
10.
Les I, Martinez M, Perez-Francisco I, Cabero M, Teijeira L, Arrazubi V, et al.
Cancers (Basel)
. 2023 Mar;
15(5).
PMID: 36900420
Immune-checkpoint inhibitors (ICIs) are antagonists of inhibitory receptors in the immune system, such as the cytotoxic T-lymphocyte-associated antigen-4, the programmed cell death protein-1 and its ligand PD-L1, and they are...